文献速递妇科

间充质分子亚型是晚期卵巢癌初次减瘤术后严重术后并发症的独立预测因素

Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2018-11-28

研究纳入1994至2011年接受初次减瘤术的III-IV期高级别浆液性卵巢癌患者329例,评估分子亚型与30天术后并发症及90天死亡率的关系。间充质亚型患者严重并发症发生率高于非间充质亚型(31.5% vs 14.8%),且在多变量模型中仍为独立预测因素(调整OR 2.14)。两组90天死亡率无统计学差异。

要点

  • 间充质亚型患者严重并发症发生率为31.5%,非间充质亚型为14.8%。
  • 间充质亚型是严重术后并发症的独立预测因素(调整OR 2.14,95%CI 1.17-3.92)。
  • 间充质亚型与非间充质亚型的90天死亡率无统计学差异。

核心结论

  • 间充质亚型是晚期高级别浆液性卵巢癌患者初次减瘤术后严重术后并发症的独立预测因素。
  • 间充质亚型可能有助于术前分子检测用于规划晚期卵巢癌患者的初次治疗。

研究设计与样本

  • 研究纳入1994至2011年接受初次减瘤术的III-IV期高级别浆液性卵巢癌患者329例,均有可用的分子分型数据。

主要发现

  • 329例患者中,68.7%为IIIC期,80.5%残留病灶≤1 cm,28.0%为间充质亚型,19.5%发生3-4级并发症,90天死亡率为5.8%。
  • 单变量分析中,间充质亚型患者严重并发症发生率高于非间充质亚型(31.5% vs 14.8%;OR 2.66,95%CI 1.51-4.69;p<0.001)。
  • 多变量模型(纳入ASA评分、术前白蛋白和手术复杂度)中,间充质亚型仍为并发症的独立预测因素(调整OR 2.14,95%CI 1.17-3.92;p=0.01)。
  • 间充质亚型与非间充质亚型的90天死亡率无统计学差异(7.6% vs 5.1%;OR 1.54,95%CI 0.59-4.05;p=0.38)。

临床怎么用

  • 作者认为,间充质亚型是严重术后并发症的独立预测因素,并增加术前分子检测用于规划晚期卵巢癌患者初次治疗的潜在用途。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the contribution of molecular subtype to 30-day postoperative complications and 90-day mortality after primary debulking surgery (PDS) in advanced stage high-grade serous ovarian cancer (HGSOC). METHODS: Patients with stages III-IV HGSOC undergoing PDS from 1994 to 2011 with available molecular subtyping were included. Residual disease (RD) status was categorized as 0, 0.1-0.5, 0.6-1.0, or >1 cm. Surgical complexity scores were calculated as high, intermediate, or low as previously published. Postoperative complications were graded according to the modified Accordion classification 0-4 scale; severe was defined as grade ≥3. Molecular subtypes were derived from Agilent 4 × 44k tumor mRNA expression profiles and categorized as mesenchymal (MES) or non-mesenchymal (non-MES). Logistic regression modeling was used to assess associations. RESULTS: Of 329 patients, 68.7% were stage IIIC, 80.5% had RD ≤1 cm, 28.0% had MES subtype, and 19.5% had a grade 3-4 complication; 90-day mortality was 5.8%. In univariate analysis, patients with MES subtype were more likely to have severe complications compared to non-MES (31.5 vs. 14.8%; OR 2.66, 95% CI 1.51-4.69; p < 0.001). MES subtype remained an independent predictor of complications (adjusted OR 2.14, 95% CI 1.17-3.92; p = 0.01) in a multivariable model which included ASA score, preoperative albumin, and surgical complexity. There was no statistical difference in 90-day mortality in patients with MES compared to non-MES subtype (7.6 vs. 5.1%; OR 1.54, 95% CI 0.59-4.05; p = 0.38). CONCLUSIONS: MES subtype is an independent predictor of severe postoperative morbidity and adds to the potential use of pre-operative molecular testing in planning primary treatment of patients with advanced ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Torres D, Kumar A, Bakkum-Gamez JN, et al. Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2018. PMID: 30503050. doi:10.1016/j.ygyno.2018.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。